Ibogaine Research Database

692 research records indexed from PubMed. Plain-language summaries where available.

Of these, 52 are human clinical studies (trials, observational studies, or case reports), 398 are preclinical (animal or lab) studies, and 112 are reviews or meta-analyses summarizing other researchers’ data. A record appearing here does not by itself mean ibogaine is proven effective for a given condition — see each condition page’s evidence breakdown for what’s actually established.

Compare evidence by condition →

All Studies (692)Depression (56)PTSD (24)Alcohol Addiction (20)Heroin Addiction (16)Opioid Addiction (15)Cocaine Addiction (15)Anxiety (13)Methamphetamine Addiction (12)Traumatic Brain Injury (2)

Studies on PTSD(16 of 692)

← Back to PTSD

Accelerated recovery using magnesium ibogaine: characterizing the subjective experience of its rapid healing from neuropsychiatric disorders.

Olash, Buchanan, Brown et al.· Npj Ment Health Res· 2026· PMID: 41620509
Preclinical (Lab)

Magnesium-ibogaine, a formulation combining ibogaine with pre- and post-treatment magnesium, was recently found to yield rapid clinical improvements in U.S. Special Operations veterans with TBI and PTSD. Yet, its therapeutic phenomenology during such healing is unknown. We analyz...

Toward a nuanced framework for the medical development of ibogaine and its analogues and derivatives: implications for psychopharmacology.

Verrico, Averill, Moore et al.· Expert Opin Drug Discov· 2026· PMID: 42400152
Review

Ibogaine is a naturally occurring indole alkaloid with suggested therapeutic potential across substance use disorders, trauma-related conditions, mood disorders, and suicidality. However, its clinical translation has been hindered by safety concerns, regulatory barriers, and unce...

Thirty Years of Ibogaine Research: A Literature Review on Clinical Perspectives.

Kervadec, Bezo, Serreau et al.· J Clin Psychopharmacol· 2026· PMID: 42228481
Review

Ibogaine has garnered interest for its potential therapeutic properties in substance use and psychiatric disorders. Unlike classic psychedelics such as psilocybin or LSD, ibogaine remains underexplored in clinical research. This review aimed to synthesize the clinical literature ...

Mystical experiences during magnesium-Ibogaine are associated with improvements in PTSD symptoms in veterans.

Brown, Lissemore, Shinozuka· Journal of affective disorders· 2026· PMID: 41265656
Observational Study

Ibogaine is an atypical psychedelic that evokes unique subjective effects, including mystical experiences. Mystical experiences have shown a mediating effect on clinical improvements following treatment with several psychedelic substances; however, the relationship between mystic...

Ibogaine's potential role in supporting reward system recovery across diagnostic boundaries.

Nicolas· Front Pharmacol· 2025· PMID: 41424776
Preclinical (Lab)

This article proposes that ibogaine's induction of GDNF, modulation of glutamate and dopamine signaling, and reopening of plasticity represent a unified mechanism capable of restoring reward system fidelity across disorders. This includes addiction, obsessive-compulsive disorder ...

Pharmacological Evaluation of Tropane Analogues at the Serotonin Transporter.

Avanes, Warren, Senthil· ACS chemical neuroscience· 2025· PMID: 40802711
Unclassified

Tropane alkaloids and their derivatives represent a diverse class of small molecules with a broad range of therapeutic applications. Many tropanes regulate synaptic levels of neuromodulators by interacting with monoamine transporters such as dopamine (DAT) and serotonin (SERT) tr...

Efficient and modular synthesis of ibogaine and related alkaloids.

Iyer, Favela, Domokos· Nature chemistry· 2025· PMID: 39915657
Preclinical (Animal)

Anecdotal reports and preliminary clinical trials suggest that the psychoactive alkaloid ibogaine and its active metabolite noribogaine have powerful anti-addictive properties, producing long-lasting therapeutic effects across a range of substance use disorders and co-occurring n...

The acceptability and feasibility of a virtual mantram program for patients with posttraumatic stress disorder and substance use disorders: mixed method results.

Ferkul, Agabani, Minami et al.· BMC Complement Med Ther· 2024· PMID: 38166894
Unclassified

There is a need for expanded options for therapeutic interventions for patients with posttraumatic stress disorder (PTSD) and substance use disorder (SUD). The study aimed to examine evidence for the feasibility, safety, and acceptability of a virtual Mantram Repetition Program f...

Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States Special Operations Forces Veterans.

Armstrong, Xin, Sepeda et al.· Mil Psychol· 2024· PMID: 38377244
Unclassified

This study evaluated prospective associations of ibogaine and 5-MeO-DMT treatment for risky alcohol use and post-traumatic stress disorder (PTSD) symptoms among United States (US) Special Operations Forces Veterans (SOFV). Data were collected during standard clinical operations a...

Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges.

Gomez-Escolar, Folch-Sanchez, Stefaniuk· CNS drugs· 2024· PMID: 39033264
Review

Mental health disorders and substance use disorders (SUDs) in particular, contribute greatly to the global burden of disease. Psychedelics, including entactogens and dissociative substances, are currently being explored for the treatment of SUDs, yet with less empirical clinical ...

What is needed for the roll-out of psychedelic treatments?

Xenakis, Shannon· Current opinion in psychiatry· 2024· PMID: 38726805
Review

The pace of psychedelic treatments continues to increase. Regulation and coherent clinical guidance have not been established. A philosophical divide limits effective resolution of a practice delivery quandary: is this primarily a pharmacological or psychotherapeutic intervention...

The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology.

Mastinu, Anyanwu, Carone· International journal of molecular sciences· 2023· PMID: 36674849
Review

The need to identify effective therapies for the treatment of psychiatric disorders is a particularly important issue in modern societies. In addition, difficulties in finding new drugs have led pharmacologists to review and re-evaluate some past molecules, including psychedelics...

Neuroimaging in psychedelic drug development: past, present, and future.

Wall, Harding, Zafar· Molecular psychiatry· 2023· PMID: 37759038
Review

Psychedelic therapy (PT) is an emerging paradigm with great transdiagnostic potential for treating psychiatric disorders, including depression, addiction, post-traumatic stress disorder, and potentially others. 'Classic' serotonergic psychedelics, such as psilocybin and lysergic ...

The substrate import mechanism of the human serotonin transporter.

Chan, Selvam, Young et al.· Biophys J· 2022· PMID: 35114149
Unclassified

The serotonin transporter (SERT) initiates the reuptake of extracellular serotonin in the synapse to terminate neurotransmission. The cryogenic electron microscopy structures of SERT bound to ibogaine and the physiological substrate serotonin resolved in different states have pro...

History and future of the Multidisciplinary Association for Psychedelic Studies (MAPS).

Emerson, Ponté, Jerome et al.· J Psychoactive Drugs· 2014· PMID: 24830183
Unclassified

This article describes the teenage vision of the founder of the Multidisciplinary Association for Psychedelic Studies (MAPS) that humanity's future would be aided by the therapeutic and spiritual potential of psychedelic substances. The article traces the trajectory of MAPS from ...

Ligand induced conformational changes of the human serotonin transporter revealed by molecular dynamics simulations.

Koldsø, Autzen, Grouleff et al.· PLoS One· 2013· PMID: 23776432
Unclassified

The competitive inhibitor cocaine and the non-competitive inhibitor ibogaine induce different conformational states of the human serotonin transporter. It has been shown from accessibility experiments that cocaine mainly induces an outward-facing conformation, while the non-compe...